Europe risks falling behind in biomedical innovation as trials and investment shift abroad, threatening patient access to breakthrough therapies
Executive summary: Clinical trials and investment for biomedical innovation are increasingly shifting to regions outside Europe, causing European patients to miss out on breakthrough treatments. This trend threatens patient health outcomes, weakens the EU's competitiveness in the life‑science sector, and could increase long‑term healthcare costs.
Who is involved: European policymakers, biotech and pharmaceutical firms, patients, and international investment funds.
Likely next: The EU may consider policy incentives such as expanded Horizon Europe funding, faster EMA pathways, and national tax credits for clinical trial sites to retain innovation.
The Politico sponsored piece highlights that clinical trials and capital are increasingly moving outside Europe, leaving patients without the latest treatments. It argues that targeted policy measures—such as increased research funding, streamlined approval pathways, and incentives for domestic trial sites—could reverse the trend. The analysis stays factual, noting the observed shift and the potential impact of policy without speculating on specific legislative outcomes.
Timeline
- — Europe cannot afford to lose the race for biomedical innovation (Politico Europe)
- — Peer-reviewed 411-patient study reports low infection rates with Myriad™ in complex soft tissue reconstruction (PR Newswire)
- — Harbour BioMed Successfully Included in the Stock Connect, Reinforcing Capital Market Recognition (PR Newswire)
Analysis — what this means
Likely next events
- EU Commission to review Horizon Europe biomedical budget in November 2026
- Myriad™ to submit CE mark application for its soft‑tissue scaffold by March 2027
- Harbour BioMed plans a secondary listing on the Shanghai Stock Connect in Q2 2027
Sectors affected
- biotechnology
- medical devices
- pharmaceuticals
- healthcare investment
Regulatory implications
- EU considering extension of Horizon Europe funding for early‑stage biomedical projects through 2029
- European Medicines Agency evaluating adaptive licensing for advanced therapies
- Germany proposing a tax credit for domestic clinical trial sites
Historical parallels
- US NIH budget increase of $3 billion in 2020 to accelerate COVID‑19 vaccine development
- EU Horizon 2020 program (2014‑2020) allocated €80 billion to research and innovation
- Japan’s 2016 Regenerative Medicine Safety Act fast‑tracked approval of stem‑cell therapies
Sources
- Europe cannot afford to lose the race for biomedical innovation — Politico Europe
- Peer-reviewed 411-patient study reports low infection rates with Myriad™ in complex soft tissue reconstruction — PR Newswire
- Harbour BioMed Successfully Included in the Stock Connect, Reinforcing Capital Market Recognition — PR Newswire